Phase 2 N=21 Driving Neuroplasticity With Nerve Stimulation and Modified CIT
Stroke · Cerebrovascular Accident
Primary: Change in Wolf Motor Function Test (WMFT), Timed Portion — -0.36; -0.18; -0.37; -0.15 log(seconds)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants
Phase 2 N=59 Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Glioblastoma · GBM · Glioma
Primary: Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 2 N=56 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Primary: Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure — 22; 18; 5; 9 Participants
Phase 2 N=278 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety: All Incidences of Erythema — 15; 10; 0 number of events
Phase 2 N=48 Saw Palmetto: Symptom Management for Men During Radiation Therapy
Prostate Cancer
Primary: Feasibility — 3; 3; 16; 6 Participants
Phase 2 N=15 Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Metastatic Breast Cancer
Primary: Axons With Abnormal Morphology — 52; 82; 2; NA percentage of axons
Phase 2 N=70 Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
Schizophrenia
Primary: Peak Plasma Concentration (Cmax) for Active Moiety — 39.6; 54.1; 53.2; 61.0 ng/mL
Phase 2 N=34 Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Assessment of Donor Stem Cell Engraftment: ANC Count — 33; 0 Participants
Phase 2 N=180 Trial of High-Dose Rifampin in Patients With TB
Tuberculosis
Primary: Steady State Pharmacokinetic Exposure of RIF — 115.6988; 201.9725; 284.4278 Ratio
Phase 2 N=35 Perioperative Therapy for Resectable Pancreatic Cancer
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
Phase 2 N=34 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression Free Survival — 18.3 months
Phase 2 N=110 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I — 1; 0; 0; 0 dose limiting toxicities
Phase 2 N=131 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis
Erosive Hand Osteoarthritis
Primary: Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16 — -10.74; -9.22 units on a scale — p=0.386
Phase 2 N=126 MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
Acute Coronary Syndrome
Primary: Change From Baseline In Percent Atheroma Volume (PAV) At Day 36 — -0.21; -0.94 change in percent — p=0.0738